Trial results

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

NCT06851962 on ClinicalTrials.gov · last registry update 2026-09-04

Finished 30 June 2026, after enrolling 92 people. Primary outcome, as filed: Comparison of HbA1c ≤7% goal at Week 24 between Pharmacogenetic-Guided and Standard Treatment in Type 2 Diabetes. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 2 times since then.

Status

COMPLETED

Phase

P4

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Fundación para la Investigación del Hospital Clínico de Valencia

Sponsor type

Other

Enrollment

92

Started

2025-05-26

Primary completion

2026-06-30 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Comparison of HbA1c ≤7% goal at Week 24 between Pharmacogenetic-Guided and Standard Treatment in Type 2 Diabetes

Conditions studied

Diabetes Mellitus Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.